Hemab Therapeutics 控股
COAG
30.07
-2.45
-7.53%
Hemab Therapeutics 控股
US · COAG
#3007 按市值排名
上市于 2026
30.07
-2.45
-7.53%
实时 - 追踪5344个代码 - 心跳于453秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了0.5个百分点。
机构持股
- 机构持股比例
- 101.07% +0.52pp
- 机构数量
- 62 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund61.69%
Mutual Fund26.64%
Hedge Fund12.58%
Individual/Insider0.26%
主要股东 截至 2026-06-30
RA Capital Management, L.P.
16.72% · 7.81M 股
Access Biotechnology
10.44% · 4.88M 股
Novo Holdings A/S
8.95% · 4.18M 股
FMR
7.92% · 3.70M 股
Capital Research
7.72% · 3.60M 股
Deep Track Capital, LP
7.71% · 3.60M 股
Avoro Capital Advisors LLC
7.06% · 3.30M 股
Sofinnova Partners SAS
5.38% · 2.51M 股
Artal Group S.A.
4.91% · 2.30M 股
Odlander, Fredrikson & Co. AB
4.06% · 1.89M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪29份申报 · 15次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 16.72% |
| Access Biotechnology | -- | 10.44% |
| Mads Behrndt-Eriksen | CFO & GM | 0.19% |
| John Michael Maraganore | Independent Chairperson | 0.08% |
| Novo Holdings A/S | -- | -- |
| Akshay Vaishnaw | Independent Director | -- |
| Linda Bain | Independent Director | -- |
| Benny Sorensen | Chief Executive Officer | -- |
| Keli Walbert | Director | -- |
| Catherine Madigan | Chief Medical Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-23 | Keli Walbert | Director | Other Derivative Acquisition | +36,000 | $35.72 |
| 2026-06-15 | RA Capital Management, L.P. | -- | Open Market Acquisition | +67,669 | $24.89–24.98 |
| 2026-05-19 | RA Capital Management, L.P. | -- | Open Market Acquisition | +4,798 | $24.94–24.97 |
| 2026-05-11 | RA Capital Management, L.P. | -- | Open Market Acquisition | +6,387 | $24.90 |
| 2026-05-10 | RA Capital Management, L.P. | -- | Open Market Acquisition | +51,258 | $24.34–25.00 |
| 2026-05-05 | RA Capital Management, L.P. | -- | Open Market Acquisition | +165,429 | $23.77–25.00 |
| 2026-05-03 | John Michael Maraganore | Independent Chairperson | Derivative Exercise and Retained | +35,948 | -- |
| 2026-05-03 | Novo Holdings A/S | -- | Derivative Exercise and Retained | +4,180,550 | -- |
| 2026-05-03 | RA Capital Management, L.P. | -- | Private Acquisition | +2,675,000 | $18.00 |
| 2026-05-03 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +4,838,086 | -- |
| 2026-05-03 | Access Biotechnology | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | John Michael Maraganore | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Novo Holdings A/S | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Akshay Vaishnaw | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Linda Bain | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Benny Sorensen | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Catherine Madigan | Chief Medical Officer | Other Derivative Acquisition | +49,016 | $18.00 |
| 2026-04-29 | Catherine Madigan | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-29 | Mads Behrndt-Eriksen | CFO & GM | Other Derivative Acquisition | +49,016 | $18.00 |
| 2026-04-29 | Mads Behrndt-Eriksen | CFO & GM | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Hemab Therapeutics 控股 讨论区 0 条评论